SynthesisVeterinary research communications2026
Serological and virological evidence of MERS-CoV infection among dromedary camels in Africa: a systematic review and Meta-analysis.
Synthesis in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a zoonotic pathogen of major public health concern due to its pandemic potential. Dromedary camels are the principal reservoir, and Africa harbors over 60% of the global dromedary population. This systematic review and meta-analysis assessed the serological, molecular, and geographical distribution of MERS-CoV infection and associated risk factors among African dromedary camels over the past decade. A systematic search of Web of Science, PubMed, Scopus, and African Journals Online (AJOL) was conducted for studies published between 2012 and 2025, following PRISMA 2020 guidelines. Thirty-nine eligible studies from 13 African countries were included, predominantly from East Africa, followed by North and West Africa. The pooled seroprevalence and viral RNA prevalence of MERS-CoV among dromedaries were 75.1% (95% CI: 68.2%-82.0%; I2 = 99.4) and 6.2% (95% CI: 3.5%-8.9%; I2 = 99.7), respectively, indicating extensive exposure history. Subgroup analysis showed regional variation, with the highest pooled seroprevalence in North Africa and highest viral RNA prevalence in West Africa (5.5%). Adult camels had higher seroprevalence (78.5%) than juvenile camels (42.5%), while viral RNA detection was slightly higher in young (5.5%). Female camels showed slightly higher (descriptive) pooled seroprevalence (69.7%) than males (65.8%), whereas males had slightly higher pooled viral RNA prevalence (5.1%) compared to females (4.0%). Nine studies examined human infection among camel handlers, yielding a pooled prevalence of 12.3% (95% CI: 1.4%-25.9%; I2 = 99.9). These findings highlight widespread MERS-CoV circulation in African camels and the urgent need for coordinated One Health surveillance to mitigate zoonotic risks.
Indexed as
Identifiers
41729334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.